Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantSelf-StudyPrevention of HIV
Apply Evidence-Based Recommendations for the Prevention of HIV Transmission
Sign In or Register to get started
Apply Evidence-Based Recommendations for the Prevention of HIV Transmission
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 5 Overview
HIV Preexposure Prophylaxis (PrEP) - 0%Topic 1
IntroductionActivities- 0%Topic 2
Persons to Consider for HIV PrEPActivities- 0%Topic 3
Recommended Regimens and Dosing for HIV PrEPActivities- 0%Topic 4
Baseline Laboratory Evaluation, Immunizations, and CounselingActivities- 0%Topic 5
Major HIV PrEP StudiesActivities- 0%Topic 6
Time to Achieve Protection after Initiating HIV PrEPActivities- 0%Topic 7
Impact of Adherence on Efficacy of HIV PrEPActivities- 0%Topic 8
Laboratory Monitoring on HIV PrEPActivities- 0%Topic 9
Acquisition of HIV in the Setting of HIV PrEPActivities- 0%Topic 10
HIV PrEP and Development of HIV Drug ResistanceActivities- 0%Topic 11
Adverse Effects of Medications Used for HIV PrEPActivities- 0%Topic 12
Changes in Sexual Practices Among Persons Receiving HIV PrEPActivities- 0%Topic 13
Discontinuing HIV PrEPActivities- 0%Topic 14
Transitioning from Nonoccupational HIV PEP to HIV PrEPActivities- 0%Topic 15
HIV PrEP UptakeActivities- 0%Topic 16
Future HIV PrEP MedicationsHIV Preexposure Prophylaxis (PrEP) Overview
About this Lesson
Last Updated: July 22nd, 2025CNE/CME Continuing Education
This lesson qualifies for:- 2 CME AMA PRA Category 1 Credits™, or
- 2 CNE contact hours and 2 CE contact hours (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: July 1st, 2017CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled HIV Preexposure Prophylaxis (PrEP) and available until September 1st, 2023.Learning Objectives
- List persons to consider who may benefit from HIV PrEP
- Explain recommendations for testing and counseling prior to starting HIV PrEP
- Discuss the recommended HIV PrEP regimens, including dosing, safety, efficacy, and clinical eligibility
- Describe recommended clinical and laboratory baseline evaluation and monitoring for persons receiving HIV PrEP
- Summarize initial management of persons who develop HIV while receiving HIV PrEP
Lesson Contributors
Authors
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneAley G. Kalapila, MD, PhDAley G. Kalapila, MD, PhD
Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health SystemDisclosures:NoneReviewers
Brian R. Wood, MDBrian R. Wood, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE approved byOregon Nurses AssociationCopyright © 2025 National HIV CurriculumThe Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745 - 0%Topic 2